The collaboration will focus on advancing Synthekine's multiple approaches to optimizing IL-10, with the goal of developing selective agonists that expand therapeutic index.
'We look forward to working with Synthekine, a leader in targeted cytokine engineering with outstanding technologies and scientific team,' said
'We are excited to partner with
Under the terms of the agreement, Synthekine and
IL-10 is an important immune-regulatory cytokine that attracted substantial clinical interest in the past for use as an immunosuppressive agent. Alongside promising efficacy, however, clinical studies of recombinant human IL-10 showed dose-limiting toxicity, due in part to IL-10's pleiotropic activity on various immune cells. Synthekine is harnessing the immunosuppressive activity of IL-10 while engineering out its immunostimulatory effects, and thus decoupling efficacy and toxicity. Learn more about Synthekine's cytokine partial agonist platform and surrogate cytokine agonist platform here.
ABOUT SYNTHEKINE
Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists.
Contact:
Tel: 619-961-8848
Email: will.zasadny@inizioevoke.com
(C) 2024 Electronic News Publishing, source